ロード中...
CRISPR/Cas9 gene editing for curing sickle cell disease
Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only four FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic...
保存先:
| 出版年: | Transfus Apher Sci |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049447/ https://ncbi.nlm.nih.gov/pubmed/33455878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.transci.2021.103060 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|